Skip to main content
Premium Trial:

Request an Annual Quote

Karo Bio Selects Elsevier's Reaxys to Support Medicinal Chemistry Projects

Premium

Elsevier said this week that Karo Bio has licensed its Reaxys suite to help its chemists identify and prioritize viable drug compounds for further research and development.

Specifically, Karo's chemists are using Elsevier's Reaxys and Reaxys Medicinal Chemistry solutions. These tools give researchers access to biological and chemistry data from periodicals, peer-reviewed journal articles, and patents.

The financial details of the agreement were not disclosed.

Elsevier's Reaxys portfolio is one of several products for drug discovery and development offered by the company's life science solutions business. Other tools in the unit include ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA, and Embase.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.